Across the United States (and soon Canada), a new chapter in weight-management culture is unfolding, one shaped by online telehealth platforms, social media influencers, and a renewed push toward the ideal of being “thin.” As interest grows, so does the trend of microdosing GLP-1 medications, originally developed to treat obesity and type-2 diabetes.
These powerful prescription injections are now being marketed on billboards, in subway corridors, and across countless digital platforms as quick, cosmetic solutions for anyone looking to slim down, even slightly. Ads highlight brides preparing for their weddings, influencers shedding a few pounds on camera, and promises of fast, dramatic results.
A Trend That’s Pushing Beyond Medical Guidelines
Although GLP-1 medications like semaglutide and tirzepatide have transformed care for people living with obesity and some chronic health conditions, they’re not approved for individuals whose BMI is below 27. Drug makers themselves, including the manufacturers of Ozempic, Wegovy, Mounjaro, and Zepbound have publicly opposed their use for cosmetic weight loss.
Physicians warn that people without medical indications may experience serious side effects with little to no health benefit, including digestive issues and potential pancreatic complications. There are also growing concerns that widespread, appearance-driven marketing could fuel unhealthy relationships with food, weight, and body image.
Telehealth’s Rapid Expansion and Limited Oversight
Loosely regulated telehealth startups have quickly filled the demand for off-label access. Many avoid naming specific drugs, instead promoting “GLP-1 microdosing” or showing generic vials. Research shows that most ads emphasize achieving a thinner body and highlight benefits far more prominently than risks.
The FDA has begun responding, issuing dozens of cease-and-desist letters urging companies to meet safety and disclosure standards similar to those required for pharmaceutical advertising. Still, access remains easy, with some consumers reporting same-day prescriptions and minimal medical verification.
Influencers, Fast Results, and New Pressures
Social media plays a significant role. With influencers sharing their own experiences, sometimes compensated, sometimes not — curiosity and demand continue to rise. Some creators openly discuss microdosing to slim down for events or maintain a specific appearance, while others have spoken about increased dependency or adverse reactions.
At the same time, more non-obese patients are now being prescribed these medications through both telehealth platforms and traditional clinics. Recent studies show that off-label use among people who are not overweight has climbed sharply over the past several years.
Navigating Wellness With Care
For travelers, spa-goers, and wellness-minded readers, the rise of cosmetic GLP-1 use underscores a larger conversation about health, body image, and the pressures amplified by modern marketing.
If considering any prescription weight-loss therapy, it’s essential to:
-
Consult a qualified healthcare provider in person
-
Discuss your medical history and long-term health goals
-
Understand both benefits and risks, including psychological impacts
-
Be cautious of unrealistic promises or shortcuts
-
Recognize that whole-body wellness includes far more than weight
At its best, wellness is thoughtful, informed, and personal, not driven by trends or pressure to conform to a single ideal of beauty. As the landscape evolves, staying grounded in balanced, evidence-based information can help travelers and consumers make choices that truly support their health and well-being.
Adapted from reporting by Jessica Nix and Madison Muller, originally published by Bloomberg News on November 24, 2025.